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Reversal of Coronary Atherosclerosis
Clinical Promise as the Basis for Noninvasive Management of Coronary Artery Disease K. Lance Gould, MD C oronary heart disease remains widely prevalent and is the leading cause of mortality and morbidity in the United States, with an estimated half-million deaths and $56 billion expended for hospital, physician, and medical-surgical costs associated with this disease.1,2 In war casualties of Korea and Vietnam, 12% to 20% of young men averaging 26 years old had coronary artery stenoses of 50% diameter narrowing or greater. [3] [4] [5] [6] It is therefore a conservative current estimate that 10% to 13% of middle-aged individuals in the United States have coronary heart disease,7-10 with up to 60% of heart attacks or sudden death occurring without prior warning symptoms sufficient to incur medical evaluation or treatment.1"- '4 For diagnosis of coronary artery disease, current cardiovascular practice focuses principally on ECG exercise testing, stress perfusion imaging, and coronary arteriography. For treatment, current cardiovascular practice focuses principally on antianginal drugs, percutaneous transluminal coronary angioplasty (PTCA), or bypass surgery. This review analyzes the basis for an alternative, comprehensive, noninvasive management of coronary artery disease using positron emission tomography (PET) perfusion imaging and vigorous risk factor modification aimed at regression of coronary atherosclerosis and stabilization of plaque to prevent the clinical events of myocardial infarction, sudden death, and unstable coronary syndromes requiring PTCA or bypass surgery. The diagnostic and therapeutic components of this approach, PET, and vigorous risk factor modification are analyzed separately and then integrated into a practical paradigm or protocol for the principally noninvasive management of coronary atherosclerosis as currently practiced by the author.
New concepts introduced into scientific literature are by definition only partially validated. When completely documented by multiple confirmatory studies, extensive data and wide acceptance, the concept is no longer new or even publishable. Therefore, to some extent this analysis reflects the author's personal perspective on current medical literature, on some data not yet published, and on his personal experience in clinical prac-tice. While a randomized clinical trial of the approach described here in comparison to mechanical revascularization would be ideal, it is germane to point out that the most widely used elective cardiology therapeutic procedure, PTCA, has never been subjected to a randomized trial of its benefits in patients with stable coronary artery disease compared with medical therapy. In contrast, vigorous risk factor modification and/or lipid lowering in several randomized trials have demonstrated partial regression of stenoses and major reduction of cardiac events as detailed subsequently. This review goes beyond the traditional summary of what has been substantially proven. Rather, it is a rational synthesis of what is feasible, strongly supported by current medical literature, and demonstrated by the author's personal clinical practice as an example beyond mere academic conjecture. While many points will be challenged as inadequately validated, the purpose of this synthesis is to detail an alternative way of thinking about the primarily noninvasive management of coronary atherosclerosis that is as rational, clinically feasible, and no less validated than current more invasive practice paradigms.
Pathophysiology
The explanation for sudden death, myocardial infarction, or unstable coronary syndromes after a prolonged silent phase of coronary atherosclerosis is most commonly rupture of an atherosclerotic plaque associated with localized coronary thrombosis and/or spasm.15-2' Plaque rupture typically occurs at milder stenoses of 40% to 60% diameter narrowing or less15-21 that may not cause symptoms or ischemia on treadmill testing, which, therefore, may not predict future coronary events. [8] [9] [10] 22 Quantitative coronary arteriography of the entire coronary vascular tree indicates that patients with segmental coronary artery narrowing, even mild narrowing, have coronary artery lumen diameters that are diffusely 30% to 50% smaller than normal subjects' for the size of the regional distal myocardial mass.23 ' The moderate inferior perfusion defect at rest becomes more intense and larger after dipyridamole. 
Economics of Reversal Treatment for
Coronary Artery Disease
Although medical care in the United States is considered optimal for those with access to it, the cost for achieving optimal outcomes is high. This inefficiency of high cost for good outcomes involves not only high-cost procedures but excessive diagnostic tests that are not definitive, unnecessary interventional procedures, and the practice pattern of "doing everything to all patients," so that overall costs are high to produce good outcomes in some individuals.94-98 Current reimbursement policies and insurance coverage provide definite economic incentives for such inefficient practice patterns. The field of healthcare is therefore focusing on containment of costs, effectiveness of outcomes, elimination of unnecessary tests or procedures, alternative less-expensive but effective treatment modalities, and alternative less-costly clinical pathways. These issues in healthcare reflect a fundamental problem long familiar to industry and business, ie, the problem of cost versus quality of product: in this case, healthcare.
Most current approaches to this problem in healthcare have used potentially counterproductive strategies of discounted fees, restricted access, second-opinion requirements, preapproval programs for many services, precertification for diagnostic testing and hospital admission, omission of services (particularly new services or new technology), and coercive forces for early discharge from hospital care. These "clamp-down" approaches may ultimately hinder optimal solutions to the problem because they disallow innovation, flexibility of developing basic, new clinical practice strategies, protocols, and technologies that provide better answers with high quality at lower cost than heavily discounted traditional practices. It is therefore important to consider reversal treatment as an alternative to the current standard practice of PTCA or bypass surgery in the management of stable coronary artery disease. However, currently only 15% to 25% of patients who have established coronary artery disease documented by PTCA or coronary bypass surgery undergo intensive cholesterol-lowering and risk management programs despite the benefits of decreased cardiac events and partial regression of disease.99,100 Analyzing why regression treatment is not more widely used requires consideration of broad practice patterns in cardiovascular medicine now being scrutinized in an environment of cost and outcome consciousness.
The most common algorithm or pathway for evaluation and treatment of coronary artery disease currently includes (1) exercise treadmill testing, (2) stress perfusion imaging, (3) coronary arteriography, (4) antianginal drugs, and (5) PTCA or coronary artery bypass surgery. Table 4 lists some of the documented limitations herence to risk factor modification, the risk of interim coronary events, the side effects and expense of cholesterol-lowering drugs, and poor clinical recognition of the benefits of reversal treatment, particularly the decreased need for PTCA and coronary artery bypass grafting and associated costs. To some extent or in some individuals, these limitations are valid. However, in comparison to the documented limitations of current practice patterns of cardiovascular medicine outlined in Table 4 , the limitations of reversal treatment are greater in perception than in fact and are readily managed in daily practice. In the author's experience, there is a large number of patients who are able and who want to undergo reversal treatment including the lifestyle changes but are not able to obtain appropriate guidance and medical management from the cardiology profession oriented toward principally invasive alternatives. Strict dietary reduction of fat to 10% or less of calories is commonly regarded as not attainable by most patients with coronary artery disease. However, a diet of less than 10% of calories as fat has been previously reported in the Life Style Heart Trial.52 In the author's reversal clinic, diets of 10% of calories as fat and high in protein are routinely achieved in patients with coronary artery disease by an individualized approach, particularly with the large number of no-fat food products now available commercially, particularly nonfat protein sources. Strong motivation is generated by the patient's reviewing his own PET scan with a physician and by the knowledge that a low fat diet combined with lipidlowering drugs is associated with relief of angina, partial reversal or stopping progression of stenoses, and prevention of clinical events such as death, myocardial infarction, bypass surgery, or balloon angioplasty in most patients. This approach nearly always combines both very low fat diet and cholesterol-lowering drugs to achieve optimal results. When it is presented appropriately and adapted to individual needs, the majority of patients will succeed in maintaining a reversal program.
While the risk of coronary events is always a concern, cholesterol-lowering trials have shown a remarkable decrease in coronary events. '15,16,1952,58,59,62,63,78 99Moreover , in patients with new-onset angina,'08 in asymptomatic or mildly symptomatic patients,'09 or even in patients with severe exercise-induced ischemia,110 ischemic episodes during daily life or with exercise do not predict future coronary events. If restenosis is considered a coronary event after PTCA and graft closure after bypass surgery, coronary events after these procedures are quite common in up to 40% of patients'01 105-more than events after a reversal program. These observations in parallel with the CASS study91 suggest that it is appropriate and safe to pursue a medical regimen, such as antianginal and reversal treatment with deferral of revascularization in most patients having stable coronary artery disease, where revascularization is an option if reversal treatment is not successful. It is therefore appropriate to treat such patients initially with reversal regimens using diet, cholesterol-lowering and antianginal drugs, antioxidants, and exercise as an alternative to PTCA or bypass surgery. 15, 16, 19, 52, 58, 59, 62, 63, 78, 91, 99 Use of cholesterol-lowering drugs requires that liver enzymes be checked monthly for 3 months after starting or changing dose of an HMG CoA reductase inhibitor 
